alpha-(2-二乙基氨基乙胺)苯乙酸异戊酯二盐酸盐 | 5892-41-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: alpha-(2-二乙基氨基乙胺)苯乙酸异戊酯二盐酸盐
• 中文别名: 盐酸卡米罗芬
• 英文名称: Camylofine dihydrochloride
• 英文别名: 3-methylbutyl 2-[2-(diethylamino)ethylamino]-2-phenylacetate;dihydrochloride
• CAS: 5892-41-1
• 化学式: C19H34Cl2N2O2
• 分子量: 393.4
• InChiKey: ZHRVNCCPAKIGRH-UHFFFAOYSA-N

物化性质

• 熔点：
  174-178°; mp 172° and 173°
• 溶解度：
  DMSO（轻微）、乙醇（轻微、超声处理）、甲醇（轻微）
• 碰撞截面：
  183.1 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  -5.19
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  47.4
• 氢给体数：
  2
• 氢受体数：
  4

制备方法与用途

类别：有毒物品

毒性分级：中毒

急性毒性：

• 口服（小鼠）LD50：760 毫克/公斤
• 皮下（小鼠）LD50：1350 毫克/公斤

可燃性危险特性：可燃；加热分解时释放有毒氮氧化物和氯化氢烟雾

储运特性：库房通风、低温干燥

灭火剂：干粉、泡沫、砂土

文献信息

• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
  申请人：Eligo Bioscience

  公开号：US11224621B2

  公开（公告）日：2022-01-18

  The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.

  本发明包括原位修饰细菌（最好是天然存在的细菌）的组合物、试剂盒和方法。通过以特定方式调节微生物组细菌群表达和/或分泌的分子，可用于治疗、预防或治愈与微生物组相关的疾病或失调。基因组修饰可以改变部分或全部这些菌群与宿主之间的相互作用，从而降低它们对宿主健康的潜在危害。本发明的组合物、试剂盒和方法不会导致这些种群直接死亡或直接显著抑制其生长。本发明还包括筛选细菌中的基因修饰、确定载体诱导这些基因突变的效率以及确定这些突变对细菌生长的影响的方法。
• DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
  申请人：The Scripps Research Institute

  公开号：EP2675893A1

  公开（公告）日：2013-12-25
• MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS
  申请人：Eligo Bioscience

  公开号：EP4069840A1

  公开（公告）日：2022-10-12
• Method of Treating Transplant Rejection and Autoimmune Diseases
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20140050694A1

  公开（公告）日：2014-02-20

  A method of treating autoimmune diseases and transplant rejection, comprising the step of treating the autoimmune or transplant patient with an effective amount of SU-5416 is disclosed.